British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome

Gut

Volumn 47, Issue SUPPL. 2, 2000, Pages

  Jones, J ^a   Spiller, R ⁱ   Read, N ^j   Silk, D ^k   Whorwell, P ^l   Boorman, J ^b   Cann, P ^c   Forbes, A ^d   Gomborone, J ^e   Heaton, K ^f   Hungin, P ^g   Kumar, D ^h   Libby, G ^e  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b Letchworth   (United Kingdom)

^c JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^d ST MARK S HOSPITAL   (United Kingdom)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

^g DURHAM UNIVERSITY   (United Kingdom)

^h ST GEORGE S HOSPITAL   (United Kingdom)

ⁱ QUEEN S MEDICAL CENTRE   (United Kingdom)

^j UNIVERSITY OF SHEFFIELD   (United Kingdom)

^k CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^l WITHINGTON HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CISAPRIDE; CODEINE; COLESTYRAMINE; LOPERAMIDE; PLACEBO; SEROTONIN ANTAGONIST; SPASMOLYTIC AGENT;

AGING; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIARRHEA; DIETARY INTAKE; DISEASE CLASSIFICATION; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; FEEDBACK SYSTEM; HUMAN; HYPERSENSITIVITY; IRRITABLE COLON; MEDICAL AUDIT; MOOD; MORTALITY; PATIENT CARE; PEPTIC ULCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; SURVIVAL RATE;

COLONIC DISEASES, FUNCTIONAL; FEMALE; GREAT BRITAIN; HOSPITALIZATION; HUMANS; MALE; PATIENT EDUCATION; PROGNOSIS; REFERRAL AND CONSULTATION;

EID: 0033673642     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (185)

1. Functional abdominal pain: Further evidence that the whole gut is affected
2. Heightened visceral sensation in functional gastrointestinal disease is not site-specific: Evidence for a generalized disorder of gut sensitivity
3. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time
4. Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome
5. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact
6. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life
7. Towards a positive diagnosis of the irritable bowel
8. Irritable bowel syndrome defined by factor analysis. Gender and race comparisons
9. Identification of sub-groups of functional gastrointestinal disorders
10. Functional bowel disorders and functional abdominal pain
11. Defecation frequency and timing, and stool form in the general population: A prospective study
12. Prevalence of gastrointestinal symptoms in the elderly: A population-based study
13. Irritable bowel syndrome in the general population
14. The epidemiology of irritable bowel syndrome in a random population: Prevalence, incidence, natural history and risk factors
15. Symptoms of irritable bowel syndrome in a British urban community: Consulters and nonconsulters
16. Peptic ulcer, non-ulcer dyspepsia and irritable bowel syndrome in the Netherlands and Japan
17. Comparison of bowel patterns in hispanics and non-hispanic whites
18. A study of irritable bowel syndrome diagnosed by Manning criteria in an African population
19. Prevalence of irritable bowel syndrome in a non-Western population
20. Health-care-seeking behaviors related to bowel complaints: Hispanics versus non-Hispanic whites
21. Epidemiology of colonic symptoms and the irritable bowel syndrome
22. Irritable bowel-type symptoms in HMO examinees. Prevalence, demographics, and clinical correlates
23. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction
24. Symptom duration in patients with irritable bowel syndrome
25. Irritable bowel syndrome. Physiological and psychological differences between diarrhea-predominant and constipation-predominant patients
26. Upper gastrointestinal and mental symptoms in the irritable bowel syndrome
27. Abnormal illness attitudes in patients with irritable bowel syndrome
28. Life events, psychiatric illness and the irritable bowel syndrome
29. Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples
30. Psychosocial factors are associated with health care seeking rather than diagnosis in irritable bowel syndrome
31. Diagnostic value of the Manning criteria in irritable bowel syndrome
32. Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive diseases or controls. Results of a multicentre inquiry
33. Is the association between irritable bowel syndrome and abuse explained by neuroticism?
34. Functional abdominal pain, psychiatric illness, and life events
35. Symptom complaints and health care seeking behavior in subjects with bowel dysfunction
36. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome
37. Symptom complaints and health care seeking behavior in subjects with bowel dysfunction
38. Do patients with irritable bowel syndrome in primary care really differ from outpatients with irritable bowel syndrome
39. Irritable bowel syndrome in the gynecological clinic. Survey of 798 new referrals
40. Gynaecological consultation in patients with the irritable bowel syndrome
41. Evidence for exacerbation of irritable bowel syndrome during menses
42. The risk of abdominal surgery in irritable bowel syndrome
43. Learned illness behavior in patients with irritable bowel syndrome and peptic ulcer
44. Selective affective biasing in recognition memory in the irritable bowel syndrome
45. Psychometric scores and persistence of irritable bowel after infectious diarrhoea
46. The clinical significance of focal active colitis
47. Why do children have chronic abdominal pain, and what happens to them when they grow up? Population base cohort study
48. Stress-induced changes in intestinal transit in the rat: A model for irritable bowel syndrome
49. Intestinal transit in anxiety and depression
50. Effects of different types of stress and of 'prokinetic' drugs on the control of the fasting motor complex in humans
51. Psychological stress and the passage of a standard meal through the stomach and small intestine in man
52. Brain-gut response to stress and cholinergic stimulation in irritable bowel syndrome: A preliminary study
53. Increased colonic motility during exposure to a stressful situation
54. Increased colonic motility during exposure to a stressful situation
55. Stress-induced gastrointestinal secretory and motor responses in rats are mediated by endogenous corticotropin-releasing factor
56. Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function
57. Corticotropin-releasing factor directly mediates colonic responses to stress
58. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome
59. Increased colonic motility during exposure to a stressful situation
60. Hyperventilation alters colonic motor and sensory function: Effects and mechanisms in humans
61. Abnormal vagal cholinergic function and psychological behaviors in irritable bowel syndrome patients: A hospital-based Oriental study
62. Evidence for autonomic nervous system imbalance in women with irritable bowel syndrome
63. Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities
64. Idiopathic autonomic denervation in eight patients presenting with functional gastrointestinal disease. A causal association?
65. Colonic myoelectric activity in the irritable bowel syndrome
66. Colonic motor and myoelectrical activity: A comparative study of normal subjects, psychoneurotic patients, and patients with irritable bowel syndrome
67. Effect of stress, meal and neostigmine on rectosigmoid electrical control activity (ECA) in normals and in irritable bowel syndrome patients
68. Postprandial colonic transit and motor activity in chronic constipation
69. Increased segmental activity and intraluminal pressures in the sigmoid colon of patients with the irritable bowel syndrome
70. Effect of anger on colon motor and myoelectric activity in irritable bowel syndrome
71. The effect of stress on colon motor and electrical activity in irritable bowel syndrome
72. Irritable bowel syndrome: Relationship of disorders in the transit of a single solid meal to symptom patterns
73. The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind cross-over study
74. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?
75. Role of loperamide and placebo in management of irritable bowel syndrome (IBS)
76. Transit through the proximal colon influences stool weight in the irritable bowel syndrome
77. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms
78. Dysmotility of the small intestine in irritable bowel syndrome
79. Ambulatory small intestinal motility in 'diarrhoea' predominant irritable bowel syndrome
80. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome
81. Tolerance for rectosigmoid distention in irritable bowel syndrome
82. Irritable bowel syndrome: Can the patient's response to colonoscopy help with diagnosis?
83. Symptoms and visceral perception in severe functional and organic dyspepsia
84. Heightened visceral sensation in functional gastrointestinal disease is not site-specific evidence for a generalized disorder of gut sensitivity
85. Patients with irritable bowel syndrome have a greater pain tolerance than normal subjects
86. Evidence for two distinct perceptual alterations in irritable bowel syndrome
87. Regional cerebral activity in normal and pathological perception of visceral pain
88. The irritable colon syndrome
89. Prognosis in the irritable bowel syndrome: A 5-year prospective study
90. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patients
91. Irritable bowel syndrome - Post salmonella infection
92. Neuronal and behavioural consequences of chemical inflammation of rat urinary bladder
93. Increased risk of irritable bowel syndrome after bacterial gastroenteritis
94. Food intolerance and the irritable bowel syndrome
95. Food intolerance: A major factor in the pathogenesis of irritable bowel syndrome
96. Abnormal colonic fermentation in irritable bowel syndrome
97. The significance of lactose malabsorption in the irritable colon syndrome
98. A comparison of symptoms after the consumption of milk or lactose-hydrolysed milk by people with self-reported severe lactose intolerance
99. Specific food intolerance: Its place as a cause of gastrointestinal symptoms
100. Food allergy and intolerance in 100 patients- local and systemic effects
101. Double blind, placebo controlled food reactions do not correlate to IgE allergy in the diagnosis of staple food related gastrointestinal symptoms
102. Survey of gastro-intestinal reactions to foods in adults in relation to atopy, presence of mucus in the stools, swelling of joints and arthralgia in patients with gastrointestinal reactions to foods
103. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients
104. Management of diarrhoeic type of irritable bowel syndrome with exclusion diet and disodium cromoglycate
105. Pavlovian conditioning of rat mucosal mast cells to secrete rat mast cell protease II
106. Release of mast cell mediators into the jejunum by cold pain stress in humans
107. How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form
108. Gastrointestinal symptoms in the irritable bowel compared with peptic ulcer and inflammatory bowel disease
109. Symptoms of irritable bowel syndrome in ulcerative colitis in remission
110. Evaluation of patients who meet clinical criteria for irritable bowel syndrome
111. French experience of Manning's criteria in the irritable bowel syndrome
112. Non-colonic features of irritable bowel syndrome
113. More accurate diagnosis of irritable bowel syndrome by the use of 'non-colonic' symptomatology
114. Bowel dysfunction in fibromyalgia syndrome
115. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease
116. Irritable bowel syndrome: Still far from a positive diagnosis
117. Is rectal biopsy necessary in irritable bowel syndrome?
118. Most patients with functional diarrhea do not have minimal forms of lymphocytic or collagenous colitis
119. Utility of screening tests in irritable bowel syndrome
120. Prediction of lactose malabsorption in referral patients
121. Prevalence of surreptitious laxative abuse in patients with diarrhoea of uncertain origin: A cost benefit analysis of a screening procedure
122. Chronic diarrhea of unknown origin
123. Does routine abdominal ultrasound enhance diagnostic accuracy in irritable bowel syndrome?
124. Is bile acid malabsorption underdiagnosed? An evaluation of accuracy of diagnosis by measurement of SeHCAT retention
125. The prevalence of bile acid malabsorption in irritable bowel syndrome and the effect of cholestyramine: An uncontrolled open multicentre study
126. Absence of histopathological changes of ileum and colon in functional chronic diarrhea associated with bile acid malabsorption, assessed by SeHCAT test: A prospective study
127. Na+-dependent bile acid transport in the ileum: The balance between diarrhea and constipation
128. Irritable bowel syndrome - Prognosis and diagnostic safety. A 5-year follow-up study
129. Problems and challenges in the design of IBS trials Part 1. A review of the experience from published trials
130. Controlled treatment trials in the irritable bowel syndrome: A critique
131. Longterm treatment of irritable bowel syndrome with cimetropium bromide: A double blind placebo controlled clinical trial
132. Double blind study of ispaghula in irritable bowel syndrome
133. Responses of consecutive patients to reassurance after gastroscopy: Results of self administered questionnaire survey
134. Two controlled evaluations of multicomponent psychological treatment of irritable bowel syndrome
135. Symptom provocation in irritable bowel syndrome. Effects of differing doses of fructose-sorbitol
136. Management of patients with food intolerance in irritable bowel syndrome: The development and use of art exclusion diet
137. Relaxation training as a treatment for irritable bowel syndrome
138. Anthropo-analytical relaxation in irritable bowel syndrome: Results 40 months later
139. Biofeedback provides long-term benefit for patients with intractable, slow and normal transit constipation
140. A controlled behavioral treatment study of irritable bowel syndrome
141. A multi-component treatment for irritable bowel syndrome
142. Two-year follow-up of behavioral treatment of irritable bowel syndrome
143. Biofeedback training in children with functional constipation. A critical review
144. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome
145. Hypnotherapy in severe irritable bowel syndrome: Further experience
146. Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome
147. Cognitive therapy for irritable bowel syndrome
148. Controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome
149. A controlled trial of psychological treatment for the irritable bowel syndrome
150. Brief psychotherapy with patients with refractory irritable bowel syndrome
151. Controlled study of psychotherapy in irritable bowel syndrome
152. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
153. Etude controlee en double aveugle Duspatalin (mebeverine) contre placebo, dans le traitement du colon irritable
154. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome
155. Mebeverine in patients with the irritable colon syndrome: Double blind study
156. The treatment of irritable bowel syndrome. Two doses of mebeverine compared
157. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome
158. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride)
159. Irritable colon syndrome treated with an antispasmodic drug
160. An assessment of dicyclomine hydrochloride ('Merbentyl') in the irritable colon syndrome
161. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk
162. A general practice study to compare alverine citrate with mebeverine hydrochloride in the treatment of irritable bowel syndrome
163. 5-Hydroxytryptamine and human small intestinal motility: Effect of inhibiting 5-hydroxytryptamine reuptake
164. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome
165. The effect of trimipramine in patients with the irritable bowel syndrome. A double-blind study
166. Preliminary report on antidepressant treatment of irritable bowel syndrome: Comments on comparison with anxiolytic therapy
167. Therapeutic usefulness of amitriptyline in spastic colon syndrome
168. Loperamide treatment of the irritable bowel syndrome
169. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea
170. Idiopathic bile acid malabsorption - A review of clinical presentation, diagnosis, and response to treatment
171. Idiopathic bile acid malabsorption: Long-term outcome
172. A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome
173. Wheat fibre and irritable bowel syndrome. A controlled trial
174. Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study
175. Bran and irritable bowel syndrome: Time for reappraisal
176. Bran supplementation in the treatment of irritable bowel syndrome
177. Optimum dosage of ispaghula husk in patients with irritable bowel syndrome: Correlation of symptom relief with whole gut transit time and stool weight
178. Comparison of various treatments for irritable bowel syndrome
179. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome
180. 'Prokinetic' treatment of constipation-predominant irritable bowel syndrome: A placebo-controlled study of cisapride
181. Peppermint oil for the irritable bowel syndrome: A multicentre trial
182. Treating irritable bowel syndrome with peppermint oil
183. Peppermint oil does not relieve the pain of irritable bowel syndrome
184. Clinical economics review: Irritable bowel syndrome
185. Medical costs in community subjects with irritable bowel syndrome